New Facility to Serve as Core Global Resource for Drug Development Programs
SAN DIEGO, Oct 17, 2006 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) announced today a multi-milliondollar agreement with one of the top five pharmaceutical companies forthe purchase and installation of a multi-component genetic analysissystem. Depending on the Illumina arrays being processed, this systemwill be capable of generating over 45 million genotypes per day, andwill represent a core support facility for the company's globalresearch teams. The Illumina genetic analysis system will be capableof running both genotyping and gene expression applications and willinclude a number of scanners and robotic components for automatedsample and array processing.
An initial project involving 3,200 samples will be run usingIllumina's Infinium(R) Assay and the HumanHap650Y BeadChip, whichprovide broad genomic coverage and the highest per-marker informationcontent of any whole-genome genotyping arrays.
"We are excited that the pharmaceutical industry is adoptinglarge-scale genotyping and that Illumina is at the forefront of thisnew technology," said Jay Flatley, Illumina President and CEO. "Thisdemonstrates that genotyping has become a robust discovery method andis now poised to move more routinely into clinical development tosupport pharmacogenomic and predictive diagnostic applications."
About Illumina
Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function.The Company's proprietary BeadArray technology - now used in leadinggenomics centers around the world - provides the throughput, costeffectiveness and flexibility necessary to enable researchers in thelife sciences and pharmaceutical industries to perform the billions oftests necessary to extract medically valuable information fromadvances in genomics and proteomics. This information will help pavethe way to personalized medicine by correlating genetic variation andgene function with particular disease states, enhancing drugdiscovery, allowing diseases to be detected earlier and morespecifically, and permitting better choices of drugs for individualpatients.
"Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: this release may contain forward-lookingstatements that involve risks and uncertainties. Among the importantfactors that could cause actual results to differ materially fromthose in any forward-looking statements are the costs and outcome ofIllumina's litigation with Affymetrix, the Company's ability to scaleand integrate technology acquired from CyVera, the ability to furtherscale oligo synthesis output and technology to satisfy market demandderiving from the Company's collaboration with Invitrogen, Illumina'sability to further develop and commercialize its BeadArraytechnologies and to deploy new gene expression and genotyping productsand applications for its platform technology, to manufacture robustSentrix(R) arrays - including HumanHap BeadChips - and Oligator(R)oligonucleotides, and other factors detailed in the Company's filingswith the Securities and Exchange Commission including its recentfilings on Forms 10-K and 10-Q or in information disclosed in publicconference calls, the date and time of which are released beforehand.Illumina disclaims any intent or obligation to update theseforward-looking statements beyond the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Jay Flatley, President & CEO, +1 858-202-4501
mbornstein@illumina.com